Right Ventricular Dysfunction in Chronic Heart Failure

Launched by UNIVERSITY OF SIENA · Aug 18, 2023

Keywords

ClinConnect Summary

This clinical trial is aimed at understanding how right ventricular dysfunction (RVD), a condition where the right side of the heart doesn’t pump blood effectively, relates to chronic heart failure (CHF). The study will look at how common RVD is among different types of heart failure, how it affects patients' health outcomes (like heart-related deaths and hospital visits), and the different ways RVD can show up in patients. Researchers will follow participants for about three years, checking in with them every six months, either in person or through virtual visits.

To be eligible for this study, participants need to have been diagnosed with chronic heart failure based on specific guidelines and tests. This means they have certain symptoms and blood test results indicating heart problems. However, there are some exclusions, such as patients with heart issues caused by lung diseases or those with specific types of heart failure that are not related to chronic conditions. This trial is not yet recruiting participants, but it aims to gather valuable information that could help improve treatment for people with chronic heart failure and right ventricular dysfunction.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with a diagnosis of chronic heart failure made according to the recommendations of the ESC guidelines through the simultaneous presence of signs and symptoms of disease associated with BNP and NT proBNP levels \> 100 and 300 pg/ml respectively which are associated with a modest increase PAPS \> 30 mmHg with or without right ventricular dilatation.
• Exclusion Criteria:
• • Patients with dyspnea of non-cardiogenic origin, related to systemic respiratory diseases, pulmonary embolism, patients with primary pulmonary hypertension will be excluded.
• • Patients with heart failure linked to primary valvular pathologies or infiltrative pathologies, secondary and on a genetic basis, patients diagnosed with acute heart failure in non-optimized therapy for at least 3 months will also be excluded. - Patients with systemic inflammatory neoplastic diseases, advanced liver and kidney diseases awaiting transplantation will be excluded.